ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

No reading has been made of this study yet; what is shown is how the rules link it today.

Why Somatostatinoma is on this study

  • ClinicalTrials.gov files the study under Somatostatinoma.
  • It is the study's main condition, by the main-condition rule: the study is compared with others under Somatostatinoma.
7 links0 made here, not in the record6 judgments1 judge (the rules as one: Rule based)2 record changes seen
Rule basedRecord updated on ClinicalTrials.gov
Oct 5Oct 12Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT02595424Cisplatin and EtoposideVersus Temozolomide andCapecitabine in PatientsWith Advanced PoorlyDifferentiated (G3)Non-Small CellGastrointestinalECOG-ACRIN Cancer Research GroPhase 2 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Oct 2 · ClinicalTrials.gov record · Version of 2026-10-02Nov 2 · ClinicalTrials.gov record · Version of 2026-11-02Version of 2026-11-02CONDITIONSSomatostatinomaThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionCarcinoma, NeuroendocrineThe registry's MeSH filing›No judgment recorded. Shown as the registry files it.DRUGSCapecitabineIntervention entry›As of now · Rule based · TestedTestedCarboplatinIntervention entry›As of now · Rule based · ComparatorComparatorCisplatinIntervention entry›As of now · Rule based · ComparatorComparatorEtoposideIntervention entry›As of now · Rule based · ComparatorComparatorTemozolomideIntervention entry›As of now · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
2 versions of the record seen on ClinicalTrials.gov, Oct 2–Nov 2 · changes seen, not judgments
As of nowSomatostatinomaRule based · main-condition ruleMain conditionCurrent
As of nowCapecitabineRule based · role ruleTestedCurrent
As of nowCarboplatinRule based · role ruleComparatorCurrent
As of nowCisplatinRule based · role ruleComparatorCurrent
As of nowEtoposideRule based · role ruleComparatorCurrent
As of nowTemozolomideRule based · role ruleTestedCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.